Akèy › Leksemi monositik egi
Etid klinik pou Leksemi monositik egi ap rekrite nan Etazini
8 etid pou Leksemi monositik egi ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT04282187Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06504459Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 13, 2026 · NCT03737955Halt Aging in Survivors of Blood Cancers
Ap rekrite
Laj 50 ak plis · Tout sèks · Mizajou Jul 1, 2026 · NCT07292272211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Jun 22, 2026 · NCT03670966Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Ap rekriteFaz 2
Laj 1 a 60 · Tout sèks · Mizajou Mar 12, 2026 · NCT03970096A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 9, 2026 · NCT06950034Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
Ap rekriteFaz 1
Laj 18 a 80 · Tout sèks · Mizajou Jan 15, 2026 · NCT06429449Sous ClinicalTrials.gov, done yo ranmase Oct 3, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.